PAK4 and neoplasm: In addition to genetic knockout models, several small-molecule PAK inhibitors—including PF-3758309, FRAX597, and the dual PAK4–NAMPT inhibitor KPT-9274—have shown potent anti-tumour activity in preclinical studies [24,25,26].